Market Overview

Jefferies Initiates Cellectis With Buy

Share:
Related
25 Stocks Moving In Wednesday's Pre-Market Session
34 Biggest Movers From Yesterday
Small-Cap Biotechs Developing Novel Gene Therapies Could Become Targets of Big Pharma (GuruFocus)

Analysts at Jefferies initiated coverage on Cellectis SA (ADR) (NASDAQ: CLLS) with a Buy rating.

The target price for Cellectis is set to $46.

Cellectis shares closed at $32.59 on Friday.

Latest Ratings for CLLS

DateFirmActionFromTo
Jun 2018OppenheimerMaintainsOutperformOutperform
Mar 2018GuggenheimInitiates Coverage OnNeutral
Sep 2017NomuraMaintainsBuy

View More Analyst Ratings for CLLS
View the Latest Analyst Ratings

Posted-In: JefferiesInitiation Analyst Ratings

 

Related Articles (CLLS)

View Comments and Join the Discussion!